BioSpace News Archive

BioMidwest

Janssen Announces Late-Breaking Data from Two Gene Therapy Programs at the American Academy of Ophthalmology 2022 Annual Meeting

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the primary results from the Phase 1/2 study evaluating the investigational gene therapy botaretigene sparoparvovec in patients with the inherited retinal disease X-linked retinitis pigmentosa associated with the retinitis pigmentosa GTPase regulator gene.

October 1, 2022
·
13 min read
Policy

Rare Disease PTEN Hamartoma Tumour Syndrome (PHTS) Granted International Classification of Diseases (ICD) Code

PTEN Research Foundation announced that the rare genetic disease, PHTS, has been given a new and unique disease code in the International Classification of Diseases revision 10, Clinical Modification system that is managed by the US Center for Disease Control and Prevention.

October 1, 2022
·
6 min read
BioMidwest

Humana significantly expands Medicare Advantage health plan offerings in 2023 with focus on greater value for members

Humana Inc. released details of its Medicare Advantage and Medicare Prescription Drug Plan offerings for 2023 – with a clear focus on benefits and support based on what its members have said they want and need.

October 1, 2022
·
13 min read
Drug Development

Belite Bio Presented 12-Month Interim Results of LBS-008 Phase 1b/2 Study in Adolescent Stargardt Disease at AAO Annual Meeting 2022

Belite Bio, Inc presented one-year data from their ongoing two-year Phase 2 clinical study of Tinlarebant in STGD1 as part of the oral presentation series at the Annual Meeting of the American Academy of Ophthalmology held during September 30 - October 3, 2022 at McCormick Place, Chicago.

October 1, 2022
·
7 min read